75N91024F00002↗
Mriglobal received this contract from Nih Nci, National Institutes of Health: $2.79M obligated so far for reference laboratory testing. It runs to 2028-04-30.
Key facts · data as of Oct 21, 2026
- Recipient
- Mriglobal
- Awarding agency
- National Institutes of Health (Department of Health and Human Services)
- Contracting office
- Nih Nci (75N910)
- Obligated to date
- $2.79M
- Potential value
- $2.79M
- Ends
- 2028-04-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 21, 2026.
Cite this page: SpendQuery, Award 75N91024F00002, data as of Oct 21, 2026, https://spendquery.com/award?id=CONT_AWD_75N91024F00002_7529_75N91023D00010_7529
Mriglobal: all federal awards · Department of Health and Human Services: spending · Nih Nci: what it buys · The follow-on: recompete brief
MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT
Up for re-bid: ends 2028-04-30. Recompete brief →
What it is
- Product or service
- Reference Laboratory Testing (PSC Q301)
- Industry
- Other Scientific and Technical Consulting Services (NAICS 541690)
- Contracting office
- Nih Nci (75N910)
- Competition
- Full and open competition
- Pricing
- Cost no fee
- How it was bought
- Single-award IDIQ · under 75N91023D00010
- Solicitation
- MARTP1-2024-02
- Where the work is
- Montgomery, MD · district MD-08
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
2 subawards totaling $2.50M (89.5% of what was obligated), as Mriglobal reported them. Primes report subawards of $30,000 or more; smaller ones and unreported ones aren't here.
| Subcontractor | Amount | Subawards | Where | First | Last |
|---|---|---|---|---|---|
| Genscript Probio USA Inc. | $2.50M | 2 | NJ | 2024-11-06 | 2026-06-26 |
The largest single subawards
| Date | To | Amount | For |
|---|---|---|---|
| 2024-11-06 | Genscript Probio USA Inc. | $1.34M | PRODUCTION OF A PRIMARY CELL BANK, PRODUCTION OF PLASMID DNA DRUG SUBSTANCE. |
| 2026-06-26 | Genscript Probio USA Inc. | $1.16M | MANUFACTURE OF DRUG PRODUCT |
Every action
3 actions since 2024-09-24. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-04-29 | P00002 | Change order | $1.27M | MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT |
| 2025-03-20 | P00001 | Administrative change | $0 | MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT |
| 2024-09-24 | 0 | $1.52M | MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗